Keyphrases
Poor Prognosis
100%
Human Breast Cancer
100%
Programmed Death-ligand 1 (PD-L1)
100%
Tumor-infiltrating Lymphocytes
100%
Signaling Pathway
14%
Overall Survival
14%
Breast Cancer Cases
14%
Luminal B
14%
L1 Signaling
14%
Immunohistochemistry
7%
Clinical Outcomes
7%
Clinical Significance
7%
Clinical Trials
7%
Tissue Microarray
7%
Basal-like
7%
Monoclonal Antibody
7%
Inhibitory Receptors
7%
Survival Analysis
7%
Antibody Targeting
7%
CD28
7%
Tumor Size
7%
Immune System
7%
Negative Regulator
7%
Tumor Immunity
7%
Human Cancer
7%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
7%
Epithelial Cancer
7%
Subset Analysis
7%
Size Grading
7%
Antibody Therapy
7%
Lymph Node Status
7%
HER2+
7%
HER2 Subtype
7%
Clinical Annotation
7%
Breast Cancer Intrinsic Subtypes
7%
Medicine and Dentistry
Breast Cancer
100%
Tumor Infiltrating Lymphocyte
100%
Programmed Death-Ligand 1
42%
Overall Survival
28%
Cell Signaling Pathway
28%
Malignant Neoplasm
14%
Neoplasm
14%
Immunohistochemistry
14%
Clinical Trial
14%
Cancer
14%
Tissue Microarray
14%
Receptor
14%
Lymph Node
14%
Monoclonal Antibody
14%
Survival Analysis
14%
Immune System
14%
Antibody Therapy
14%
Diseases
14%
Biochemistry, Genetics and Molecular Biology
Tumor-Infiltrating Lymphocytes
100%
PD-L1
42%
Overall Survival
28%
Clinical Trial
14%
Monoclonal Antibody
14%
Tissue Microarray
14%
Tumor Volume
14%
Immunity
14%
CD28
14%
Immunology and Microbiology
Tumor-Infiltrating Lymphocytes
100%
Programmed Death-Ligand 1
42%
Overall Survival
28%
Monoclonal Antibody
14%
Lymph Node
14%
CD28
14%
Tumor Volume
14%
Immune System
14%